Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cephalosporin derivative

A compound and hydrate technology, applied in the field of medicine, can solve the problems of not providing pharmacological activity and drug resistance

Active Publication Date: 2008-06-04
JILIN ZHENAO PHARMA CO LTD
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Cefodizime is a semi-synthetic third-generation cephalosporin antibiotic, which was first launched in Japan in 1990. It has antibacterial activity against Gram-positive bacteria and Gram-negative bacteria, is stable to β-lactamase, and is resistant to cephalosporinase. It is extremely stable with penicillinase, but it also produces drug resistance due to long-term application. Patent US4278793 also discloses a variety of similar compounds, but does not provide pharmacological activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cephalosporin derivative
  • Cephalosporin derivative
  • Cephalosporin derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0137] The preparation method one of embodiment 1 compound A and its sodium salt A'

[0138] (1) (6R, 7R)-7-[2-[(5-amino-1,2,4-thiadiazol-3-yl)-2-oximino]acetamido]-3-acetoxymethyl Preparation of yl-5-thia-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

[0139] In the dry reaction bottle, add 27.2g 7-ACA (0.1mol), 40.5g (0.12mol) (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl) - 2-oximinothioacetic acid (S-2-benzothiazole) ester and 500ml of dichloromethane, stir rapidly and control the temperature below 5°C, adjust the pH to 8 with triethylamine, quickly warm up to room temperature, and react 4 Hour. After the reaction was completed, the reaction solution was extracted twice with water (100ml / time), and the pH was adjusted to 2 to 3 with 2mol / L dilute hydrochloric acid after merging the water phases. A white solid was precipitated, filtered, and dried in vacuo to obtain 34.8g of a white solid. The yield was 78.7%.

[0140] (2) (6R, 7R)-7-[2-[(5-amino-1,2,4-thiadiazol-3-yl)-...

Embodiment 2

[0150] The preparation method two of embodiment 2 compound A and its sodium salt A'

[0151] (1) (6R, 7R)-7-amino-3-(4-methyl-5-acetoxy-thiazol-2-yl)thiomethyl-8-oxo-5-thia-1-aza Preparation of bicyclo[4.2.0]oct-2-ene-2-carboxylic acid

[0152] Add (6R,7R)-7-amino-3-(acetoxy)methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]octane-2 to the Erlenmeyer flask -Alkene-2-carboxylic acid (ie 7-ACA) 2.8g (0.01mol), water 15ml, shake to make a uniform suspension for use. Add 2.9g (0.015mol) of 2-mercapto-4-methyl-5-thiazoleacetic acid and 40ml of water into a 250ml three-necked flask, add 0.56g (0.014mol) of NaOH solid in batches under stirring, and then use saturated NaHCO 3 Adjust the pH of the solution to 6.4, control the temperature in a water bath at 70°C, then add 7-ACA suspension dropwise and add saturated NaHCO dropwise 3 solution to make the pH of the reaction solution about 6.4, add it in 15 minutes, react for 35 minutes after the addition, then add activated carbon and stir for 1...

Embodiment 3

[0164] The preparation method one of embodiment 3 compound B and its sodium salt B'

[0165] (1) (6R, 7R)-7-[2-[(5-amino-1,2,4-thiadiazol-3-yl)-Z-2-(methoxyimino)]acetamido] - Preparation of 3-acetoxymethyl-5-thia-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

[0166] In a dry reaction flask, sequentially add (6R,7R)-7-amino-3-(acetyloxy)methyl-8-oxo-5-thia-1-azabicyclo[4.2.0] Oct-2-ene-2-carboxylic acid (7-ACA) 27.2g (0.1mol), (Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-Z- 43.9 g (0.12 mol) of 2-(methoxyimino)thioacetic acid (S-2-benzothiazole) ester and 500 ml of dichloromethane, stir rapidly and control the temperature below 5°C, adjust the pH to 8 with triethylamine , rapidly warming up to room temperature, reacted for 4 hours, extracted the reaction solution with water twice (100ml / time) after the completion of the reaction, adjusted the pH to 2-3 with 2mol / L dilute hydrochloric acid after the combined water phase, separated out a white solid, filtered, vacuum After...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to compounds of novel cephalosporin derivatives as well as pharmaceutically acceptable salts, easy hydrolysis ester, isomer, hydrates and hydrates of salts or esters thereof shown in the general formula (1), wherein, R<1>, R<2>, R<3>, R<4>, R<5> and R<6> are defined as the instruction. The invention also relates to the preparation methods of the compounds, medical composition, which contains the compounds, and the application of the compounds in preparation of drugs, which are used for curing and / or preventing diseases caused by viral infection, and pertains to the field of medical technologies.

Description

1. Technical field [0001] The present invention relates to new cephalosporin derivatives, their pharmaceutically acceptable salts, their easily hydrolyzed esters, their isomers, their hydrates and the hydrates of their salts or esters, and the preparation methods of these compounds, which contain these The pharmaceutical composition of the compounds and the use of these compounds in the preparation of medicines for treating and / or preventing infectious diseases belong to the technical field of medicine. 2. Background technology [0002] Cephalosporin antibiotics are widely used in clinical antibacterial drugs and have been developed to the fourth generation. However, due to long-term clinical use, bacteria are resistant to cephalosporin antibiotics, which greatly affects the antibacterial efficacy of cephalosporin antibiotics. In particular, infectious diseases caused by methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae, and drug-resi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D501/36A61K31/546A61P31/04
CPCY02P20/55
Inventor 黄振华
Owner JILIN ZHENAO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com